Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | BRD1 | O95696 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MGAM | O43451 | 3/20 | 0.40 |
| ▸ | SI | P14410 | 3/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508716 | 0.87 | ALDH1A1 (0.42) | PKMMAPTNPC1RAB9APKLR | |
| SCHEMBL2558135 | 0.83 | ALDH1A1 (0.44) | MAPTRAB9AALDH1A1HSD17B10TDP1 | |
| SCHEMBL10075588 | 0.81 | ALDH1A1 (0.42) | PKMMAPTNPC1RAB9APKLR | |
| SCHEMBL2007337 | 0.80 | NPC1 (0.41) | PKMMAPTNPC1RAB9APKLR | |
| SCHEMBL2007338 | 0.80 | NPC1 (0.41) | PKMMAPTNPC1RAB9APKLR | |
| SCHEMBL5313163 | 0.79 | HDAC3 (0.45) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL12466081 | 0.78 | KDM1A (0.50) | PKMMAPTNPC1RAB9ACTSB | |
| SCHEMBL13423117 | 0.78 | COXFA4 (0.44) | PKMMAPTNPC1RAB9APKLR | |
| SCHEMBL6849624 | 0.76 | PKM (0.49) | PKMMAPTNPC1RAB9APKLR | |
| SCHEMBL12465725 | 0.75 | PKM (0.41) | PKMMAPTNPC1RAB9APKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179343-A1 | METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-07-15 | — | — | US | claimed |
| WO-2008121074-A1 | METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-10-09 | — | — | WO | claimed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10738062-B2 | Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190185486-A1 | CHROMANE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179343-A1 | METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE | TDO2, AOX1, DAO | PKM 3214/4885MAPT 4873/4885NPC1 4542/4885 |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | PKM 3842/4885MAPT 4276/4885NPC1 3615/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | PKM 4353/4885MAPT 1886/4885NPC1 4542/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | PKM 3928/4885MAPT 2072/4885NPC1 2933/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | PKM 3817/4885MAPT 4443/4885NPC1 2689/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | PKM 3817/4885MAPT 4443/4885NPC1 2689/4885 |
| US-10738062-B2 | Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases | HAVCR2, C3AR1, HCCS | PKM 4308/4885MAPT 3055/4885NPC1 207/4885 |
| US-20190185486-A1 | CHROMANE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, C3AR1, HCCS | PKM 4308/4885MAPT 3055/4885NPC1 207/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | PKM 3928/4885MAPT 2072/4885NPC1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.